Senores Pharmaceuticals to Host Q4FY26 Earnings Conference Call on May 14, 2026
Senores Pharmaceuticals has announced a Q4FY26 earnings conference call on May 14, 2026, at 5:00 PM IST, following the release of its audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026. The call, moderated by Gaurav Tinani of Ambit Capital, will feature Managing Director Swapnil Shah, Chairman Sanjay Majmudar, and Whole Time Director & CFO Deval Shah. Dial-in access is available across India, Singapore, Hong Kong, USA, and UK, with the audio recording and transcript to be published on the company's website post-call.
*this image is generated using AI for illustrative purposes only.
Senores Pharmaceuticals has announced an earnings conference call for Q4FY26, scheduled for Thursday, May 14, 2026, at 5:00 PM IST. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call will be held following the announcement of the company's audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.
Company Representatives and Moderator
The earnings call will feature participation from senior leadership of Senores Pharmaceuticals. The teleconference will be moderated by Gaurav Tinani from Institutional Equities at Ambit Capital, which is hosting the event.
The following company representatives are scheduled to participate:
- Mr. Swapnil Shah – Managing Director
- Mr. Sanjay Majmudar – Chairman
- Mr. Deval Shah – Whole Time Director & Chief Financial Officer
Conference Call Access Details
Participants are encouraged to join via DiamondPass to avoid wait time. The following dial-in numbers have been provided for access:
| Parameter: | Details |
|---|---|
| Date: | May 14, 2026 |
| Time: | 5:00 PM IST |
| Primary Access (India): | +91 22 6280 1148 / +91 22 7115 8049 |
| Singapore (Toll Free): | 800 101 2045 |
| Hong Kong (Toll Free): | 800 964 448 |
| USA (Toll Free): | 1 866 746 2133 |
| UK (Toll Free): | 0 808 101 1573 |
Participants are requested to dial in a few minutes prior to the scheduled start time.
Post-Call Publication
Following the earnings conference call, the audio recording and transcript will be published on the official website of Senores Pharmaceuticals. The company has indicated that a separate intimation will be provided once these materials are made available. The intimation was signed by Vinay Kumar Mishra, Company Secretary and Compliance Officer (ICSI Membership No.: F11464), on May 08, 2026.
Historical Stock Returns for Senores Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.62% | +7.38% | +25.02% | +17.33% | +95.02% | +73.33% |
What revenue growth trajectory and margin expansion can investors expect from Senores Pharmaceuticals for FY27 given its pipeline developments and geographic expansion plans?
How is Senores Pharmaceuticals positioning itself in key regulated markets like the US and Europe, and what ANDA approvals or product launches are anticipated in the near term?
Will Senores Pharmaceuticals announce any strategic acquisitions, partnerships, or capacity expansion initiatives during or following the Q4FY26 earnings call?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
